Endocannabinoids accumulate in spinal cord of SOD1G93A transgenic mice

Journal of Neurochemistry

Volumn 89, Issue 6, 2004, Pages 1555-1557

  Witting, Anke ^a   Weydt, Patrick ^a,b   Hong, Soyon ^a   Kliot, Michel ^a   Moller, Thomas ^b   Stella, Nephi ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ALS; Cannabinoid; Endocannabinoid; Lipids; SOD1

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; GENE MUTATION; LUMBAR SPINAL CORD; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; TRANSGENIC MOUSE;

AGE FACTORS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ARACHIDONIC ACIDS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOCANNABINOIDS; GLYCERIDES; LUMBOSACRAL REGION; MALE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; POLYUNSATURATED ALKAMIDES; SPINAL CORD; SUPEROXIDE DISMUTASE;

ANIMALIA; MUS MUSCULUS;

EID: 3042559925     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02544.x     Document Type: Article

References (21)

1. Alexianu M. E., Kozovska M. and Appel S. H. (2001) Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57, 1282-1289.
2. Baker D., Pryce G., Croxford L. J., Brown P., Pertwee R. G., Makriyannis A., Knanolkar A., Layward L., Fezza F., Bisogno T. and DiMarzo V. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300-302.
3. Cleveland D. W. and Rothstein J. D. (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev. Neurosci. 2, 806-819.
4. Franklin A., Parmentier-Batteur S., Walter L., Greenberg D. A. and Stella N. (2003) Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cells motility. J. Neurosci. 23, 7767-7775.
5. Hall E. D., Oostveen J. A. and Gurney M. E. (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249-256.
6. Klegeris A., Bissonnette C. J. and McGeer P. L. (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharm. 139, 775-786.
7. Maccarrone M., Valverde O., Barbaccia M. L., Castane A., Maldonado R., Ledent C., Parmentier M. and Finazzi-Agro A. (2002) Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J. Neurosci. 15, 1178-1186.
8. Marsicano G., Goodenough S., Monory K. et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88.
9. Mourelatos Z., Gonatas N. K., Stieber A., Gurney M. E. and Dal Canto M. C. (1996) The golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Proc. Nat. Acad. Sci. USA 93, 5472-5477.
10. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R. and Shohami E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531.
11. Parmentier-Batteur S., Jin K., Ou Mao X., Xie L. and Greenberg D. A. (2002) Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci. 22, 9771-9775.
12. Piomelli D., Giuffrida A., Calignano A. and Rodrigueza de Fonseca F. (2000) The endocannabinoid system as a target for therapeutic drugs. TIPS 21, 218-224.
13. Schabitz W.-R., Giuffrida A., Berger C., Aschoff A., Schwaninger M., Schwab S. and Piomelli D. (2002) Release of fatty acid amides in a patient with hemispheric stroke. Stroke 33, 2112-2114.
14. Troost D., Claessen N., van den Oord J. J., Swaab D. F. and de Jong J. M. (1993) Neuronophagia in the motor cortex in amyotrophic lateral sclerosis. Neuropathol Appl. Neurobiol. 19, 390-397.
15. Walter L. and Stella L. (2003) Endothelin-1 increases 2-arachidonyl glycerol (2-AG) production in astrocytes. Glia 44, 85-90.
16. Walter L. and Stella N. (2004) Cannabinoids and neuroinflammation. Br. J Pharmacol. 141, 775-785.
17. Walter L., Franklin A., Witting A. M., Möller T. and Stella N. (2002) Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem. 277, 20869-20876.
18. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K. and Stella N. (2003) Non-psychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23, 1398-1405.
19. Wang L., Liu J., Harvey-White J., Zimmer A. and Kunos G. (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc. Natl Acad. Sci. USA 100, 1393-1398.
20. Weydt P., Hong S. Y., Kliot M. and Möller T. (2003) Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 14, 1051-1055.
21. Wilson R. I. and Nicoll R. A. (2002) Endocannabinoid signaling in the brain. Science 296, 678-682.